Versican Plus DHPPi/L4R

Country: European Union

Language: Icelandic

Source: EMA (European Medicines Agency)

Active ingredient:

hundur illt í maga veira, álag CDV Bio 11/A, hundur brottfall tegund 2, álag CAV-2 Bio 13, hundur parvóveiru tegund 2b, álag CPV-2b Bio 12/B, hundur inflúensubróðir tegund 2 veira, álag CPiV-2 Bio 15 (allir lifandi, bæklaða), Leptospira interrogans serogroup Australis serovar Bratislava, álag MSLB 1088, L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, álag MSLB 1089, L. interrogans serogroup Canicola serovar Canicola, álag MSLB 1090, L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa, álag MSLB 1091...

Available from:

Zoetis Belgium SA

ATC code:

QI07AJ06

INN (International Name):

live, attenuated Canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus inactivated and Leptospira

Therapeutic group:

Hundar

Therapeutic area:

lifandi hundur illt í maga veira + lifandi hundur brottfall + lifandi parainfl.veira + lifandi hundur parvóveiru + óvirkt hundaæði + óvirkt leptospira, Ónæmislyf fyrir canidae

Therapeutic indications:

Virk bólusetningar hunda frá 8-9 vikna:til að koma í veg fyrir dauða og klínískum merki af völdum hundur illt í maga veira,til að koma í veg fyrir dauða og klínískum merki af völdum hundur brottfall tegund 1,til að koma í veg fyrir klínískum merki og draga úr veiru skilst af völdum hundur brottfall tegund 2,til að koma í veg fyrir klínískum merki, leucopoenia og veiru skilst af völdum hundur parvóveiru,til að koma í veg fyrir klínískum merki (nef og augu útskrift) og draga úr veiru skilst af völdum hundur inflúensubróðir veira,til að koma í veg fyrir klínískum merki, sýkingum og þvagi af völdum L. interrogans serogroup Australis serovar Bratislava,til að koma í veg fyrir klínískum merki og þvagi og draga úr sýkingu af völdum L. interrogans serogroup Canicola serovar Canicola og L. interrogans serogroup Icterohaemorrhagie serovar Icterohaemorrhagiae,til að koma í veg fyrir klínískum merki og draga úr sýkingu og þvagi af völdum L. interrogans serogroup Grippotyphosa serovar Grippotyphosa og til að koma í veg fyrir dauðsföll, klínísk einkenni og sýkingar af völdum hundaæði.

Product summary:

Revision: 6

Authorization status:

Leyfilegt

Authorization date:

2014-05-06

Patient Information leaflet

                                17
B. FYLGISEÐILL
18
FYLGISEÐILL:
VERSICAN PLUS DHPPI/L4R FROSTÞURRKAÐ STUNGULYF OG DREIFA, DREIFA,
FYRIR HUNDA
1.
HEITI OG HEIMILISFANG MARKAÐSLEYFISHAFA OG ÞESS FRAMLEIÐANDA
SEM BER ÁBYRGÐ Á LOKASAMÞYKKT, EF ANNAR
Markaðsleyfishafi:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGÍA
Framleiðandi sem ber ábyrgð á lokasamþykkt:
Bioveta, a.s.,
Komenského 212,
683 23 Ivanovice na Hané,
TÉKKLAND
2.
HEITI DÝRALYFS
Versican Plus DHPPi/L4R frostþurrkað stungulyf og dreifa, dreifa,
fyrir hunda
3.
VIRK(T) INNIHALDSEFNI OG ÖNNUR INNIHALDSEFNI
Hver 1 ml skammtur inniheldur:
VIRK INNIHALDSEFNI:
FROSTÞURRKAÐ LYF (LIFANDI VEIKLAÐ):_ _
LÁGMARK
HÁMARK_ _
Hundafársveira, stofn CDV Bio 11/A
10
3,1
TCID
50
*
10
5,1
TCID
50
Hundaadenóveira, tegund 2, stofn CAV-2-Bio 13
10
3,6
TCID
50
*
10
5,3
TCID
50
Hundaparvóveira tegund 2b, stofn CPV-2b-Bio 12/B
10
4,3
TCID
50
*
10
6,6
TCID
50
Hundaparainflúensuveira tegund 2, stofn CPiV-2-Bio 15
10
3,1
TCID
50
*
10
5,1
TCID
50
DREIFA (ÓVIRKJUÐ):
_Leptospira interrogans_
sermihópur Icterohaemorrhagiae
sermigerð Icterohaemorrhagiae stofn MSLB 1089
ALR** títri ≥1:51
_Leptospira interrogans _
sermihópur Canicola
sermigerð Canicola, stofn MSLB 1090
ALR** títri ≥1:51
_Leptospira kirschneri _
sermihópur Grippotyphosa
sermigerð Grippotyphosa
_,_
stofn MSLB 1091
ALR** títri ≥1:40
_Leptospira interrogans_
sermihópur Australis
_ _
sermigerð Bratislava
_,_
stofn MSLB 1088
ALR** títri ≥1:51
Hundaæðiveira, stofn SAD Vnukovo-32
≥2,0 a.e.***
ÓNÆMISGLÆÐAR:
Álhýdroxíð
1,8 – 2,2 mg.
*
Skammtur sem dugar til að sýkja 50% smitaðra vefjarækta (tissue
culture infectious dose 50%).
**
Mótefnaörkekkjunarpróf (antibody micro agglutination-lytic
reaction).
*** Alþjóðlegar einingar.
19
Frostþurrkað lyf: svampkennt hvítt efni.
Dreifa: bleiklitaður með fíngerðu botnfalli.
4.
ÁBENDING(AR)
Virk ónæmingaraðgerð hjá hundum frá 8-9 vikna aldri:
-
til að koma í veg fyrir dauðsföll og klínísk einkenni af völdum
hunda
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
VIÐAUKI I
SAMANTEKT Á EIGINLEIKUM LYFS
2
1.
HEITI DÝRALYFS
Versican Plus DHPPi/L4R frostþurrkað stungulyf og dreifa, dreifa,
fyrir hunda
2.
INNIHALDSLÝSING
Hver 1 ml skammtur inniheldur:
VIRK INNIHALDSEFNI:
FROSTÞURRKAÐ LYF (LIFANDI VEIKLAÐ):_ _
LÁGMARK
HÁMARK_ _
Hundafársveira, stofn CDV Bio 11/A
10
3,1
TCID
50
*
10
5,1
TCID
50
Hundaadenóveira, tegund 2, stofn CAV-2-Bio 13
10
3,6
TCID
50
*
10
5,3
TCID
50
Hundaparvóveira tegund 2b, stofn CPV-2b-Bio 12/B
10
4,3
TCID
50
*
10
6,6
TCID
50
Hundaparainflúensuveira tegund 2, stofn CPiV-2-Bio 15
10
3,1
TCID
50
*
10
5,1
TCID
50
DREIFA (ÓVIRKJUÐ):
_Leptospira interrogans_
sermihópur Icterohaemorrhagiae
sermigerð Icterohaemorrhagiae stofn MSLB 1089
ALR** títri ≥1:51
_Leptospira interrogans _
sermihópur Canicola
sermigerð Canicola, stofn MSLB 1090
ALR** títri ≥1:51
_Leptospira kirschneri _
sermihópur Grippotyphosa
sermigerð Grippotyphosa
_,_
stofn MSLB 1091
ALR** títri ≥1:40
_Leptospira interrogans_
sermihópur Australis
_ _
sermigerð Bratislava
_,_
stofn MSLB 1088
ALR** títri ≥1:51
Hundaæðiveira, stofn SAD Vnukovo-32
≥2,0 a.e.***
*
Skammtur sem dugar til að sýkja 50% smitaðra vefjarækta (tissue
culture infectious dose 50%).
**
Mótefnaörkekkjunarpróf (antibody micro agglutination-lytic
reaction).
*** Alþjóðlegar einingar.
ÓNÆMISGLÆÐAR:
Álhýdroxíð
1,8 – 2,2 mg.
Sjá lista yfir öll hjálparefni í kafla 6.1.
3.
LYFJAFORM
Frostþurrkað stungulyf og dreifa, dreifa.
Útlit lyfsins er sem hér segir:
Frostþurrkað lyf: svampkennt hvítt efni.
Dreifa: hvítleit með fíngerðu botnfalli.
4.
KLÍNÍSKAR UPPLÝSINGAR
4.1
DÝRATEGUNDIR
Hundar
3
4.2
ÁBENDINGAR FYRIR TILGREINDAR DÝRATEGUNDIR
Virk ónæmingaraðgerð hjá hundum frá 8-9 vikna aldri:
-
til að koma í veg fyrir dauðsföll og klínísk einkenni af völdum
hundafársveiru,
-
til að koma í veg fyrir dauðsföll og klínísk einkenni af völdum
hundaadenóveiru af tegund 1,
-
til að koma í veg fyrir klínísk einkenni af völdum
hundaadenóveiru af tegun
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-05-2019
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-05-2019
Public Assessment Report Public Assessment Report Bulgarian 28-04-2015
Patient Information leaflet Patient Information leaflet Spanish 16-05-2019
Public Assessment Report Public Assessment Report Spanish 28-04-2015
Patient Information leaflet Patient Information leaflet Czech 16-05-2019
Public Assessment Report Public Assessment Report Czech 28-04-2015
Patient Information leaflet Patient Information leaflet Danish 16-05-2019
Public Assessment Report Public Assessment Report Danish 28-04-2015
Patient Information leaflet Patient Information leaflet German 16-05-2019
Public Assessment Report Public Assessment Report German 28-04-2015
Patient Information leaflet Patient Information leaflet Estonian 16-05-2019
Public Assessment Report Public Assessment Report Estonian 28-04-2015
Patient Information leaflet Patient Information leaflet Greek 16-05-2019
Public Assessment Report Public Assessment Report Greek 28-04-2015
Patient Information leaflet Patient Information leaflet English 16-05-2019
Public Assessment Report Public Assessment Report English 28-04-2015
Patient Information leaflet Patient Information leaflet French 16-05-2019
Public Assessment Report Public Assessment Report French 28-04-2015
Patient Information leaflet Patient Information leaflet Italian 16-05-2019
Public Assessment Report Public Assessment Report Italian 28-04-2015
Patient Information leaflet Patient Information leaflet Latvian 16-05-2019
Public Assessment Report Public Assessment Report Latvian 28-04-2015
Patient Information leaflet Patient Information leaflet Lithuanian 16-05-2019
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-05-2019
Public Assessment Report Public Assessment Report Lithuanian 28-04-2015
Patient Information leaflet Patient Information leaflet Hungarian 16-05-2019
Summary of Product characteristics Summary of Product characteristics Hungarian 16-05-2019
Public Assessment Report Public Assessment Report Hungarian 28-04-2015
Patient Information leaflet Patient Information leaflet Maltese 16-05-2019
Public Assessment Report Public Assessment Report Maltese 28-04-2015
Patient Information leaflet Patient Information leaflet Dutch 16-05-2019
Public Assessment Report Public Assessment Report Dutch 28-04-2015
Patient Information leaflet Patient Information leaflet Polish 16-05-2019
Public Assessment Report Public Assessment Report Polish 28-04-2015
Patient Information leaflet Patient Information leaflet Portuguese 16-05-2019
Summary of Product characteristics Summary of Product characteristics Portuguese 16-05-2019
Public Assessment Report Public Assessment Report Portuguese 28-04-2015
Patient Information leaflet Patient Information leaflet Romanian 16-05-2019
Public Assessment Report Public Assessment Report Romanian 28-04-2015
Patient Information leaflet Patient Information leaflet Slovak 16-05-2019
Public Assessment Report Public Assessment Report Slovak 28-04-2015
Patient Information leaflet Patient Information leaflet Slovenian 16-05-2019
Summary of Product characteristics Summary of Product characteristics Slovenian 16-05-2019
Public Assessment Report Public Assessment Report Slovenian 28-04-2015
Patient Information leaflet Patient Information leaflet Finnish 16-05-2019
Public Assessment Report Public Assessment Report Finnish 28-04-2015
Patient Information leaflet Patient Information leaflet Swedish 16-05-2019
Public Assessment Report Public Assessment Report Swedish 28-04-2015
Patient Information leaflet Patient Information leaflet Norwegian 16-05-2019
Summary of Product characteristics Summary of Product characteristics Norwegian 16-05-2019
Patient Information leaflet Patient Information leaflet Croatian 16-05-2019
Public Assessment Report Public Assessment Report Croatian 28-04-2015